Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 100$ stock price

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 15, 2021 11:56am

238 Views

Post# 32568302

RE:RE:RE:100$ stock price

Marky1 wrote: Great point,,, but the 4B$ is USD.....So actually, the MC would be Over 5B$ CDN....I think that a fair stock count would be 50 M. up from its 38.6M as shown on TD Waterhouse page....So, the 2 numbers together give you 100$ a share....no?

Good point on the USD amount.

Now look on page 31 of the company presentation to calculate a fully diluted number.

Then make sure you add a reasonable number for an AH roll-in (10-15 percent) is my guess.

Now we're much closer to 60M shares.

Don't forget future options, RSUs, etc ...

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo